RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 02, 2005, titled 'Ranbaxy Sets Up Additional Manufacturing Facility In Malaysia; Prepares To Meet Growing Demand For Generics In the Asean Region', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has on July 25, 2005, announced that Nihon Pharmaceutical Industry Ltd. (NPI), a Joint Venture between RLL and Nippon Chemiphar Limited (NC), has launched its first co-developed product, Vogseal 0.2mg and 0.3mg tablets (Generic-Voglibose) in Japan. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company on July 21,2005 titled "Ranbaxy gains tentative approval to market Glimepiride tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 14,2005 titled "Ranbaxy receives USFDA approval for Zidovudine Tablets". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company on July 05,2005 titled "Ranbaxy to market Doktor Mom Herbal brand range manufactured by J.B.Chemcials, in Romania" . The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 04,2005 titled "Ranbaxy gains approval to market METFORMIN XL Tablets,750 mg-Representing 100th ANDA approval held by Ranbaxy". The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled "Ranbaxy receives tentative approval to market Terbinafine Hydrochloride 250 MG Tablets", being issued by the Company on June 22, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled "Ranbaxy Pharmaceuticals Inc.,USA,receives prestigious outstanding supplier award from WAL-MART" being issued on June 21,2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled 'RANBAXY ACQUIRES GENERIC PRODUCT PORTFOLIO FROM EFARMES OF SPAIN', being issued by the Company. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 02, 2005, titled "Ranbaxy's Goa (India) Manufacturing Plant Receives MHRA, UK Approval", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 31, 2005, titled "RANBAXY RECEIVES INDIA'S FIRST APPROVAL FROM USFDA FOR AN ANTI RETROVIRAL DRUG UNDER THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF INITIATIVE (PEPFAR)", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 27, 2005, titled "RANBAXY HIV UPDATE". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 24, 2005, titled "RANBAXY ANNOUNCES THE LAUNCH OF CLARITHROMYCIN IR 250 MG and 500 MG TABLETS IN USA", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated May 12, 2005 titled "Ranbaxy HIV Update - May 2005." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated April 28,2005 titled "Ranbaxy Q1,05 Global Sales at USD 261 Mn - Board recommends Final dividend of Rs 12 per share for 2004, Announces Stock Split " . The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has entered into a collaborative agreement with the National Chemical Laboratories (NCL), Pune and the Department of Science & Technology (DST), New Delhi, in the area of New Drug Discovery. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated April 12, 2005, titled 'RANBAXY VOLUNTARILY DISCONTINUES VALDECOXIB FOLLOWING USFDA's CAUTIONARY VIEWS ON INNOVATOR PFIZER's BEXTRA'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release titled "Joint Announcement by Ranbaxy(UK) Ltd. and The Department of Health" on April 01,2005. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release titled "Ranbaxy receives FDA Approval to Market a Generic Alternative to Macrobid� on April 01,2005. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated March 29, 2005, titled 'Austrian Patent Office issues favourable ruling for Ranbaxy on Atorvastatin - Pfizer's patent claims for enantiomeric form held invalid.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated March 30, 2005, titled 'Ranbaxy to Appeal Preliminary Injunction Against Sales of Quinapril.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated March 23, 2005 tilted "Ranbaxy HIV Update-March 2005". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated March 11,2005 titled "Ranbaxy announces new structure for research & development focus on dual areas of drug discovery and Generics/NDDS/Drug Development". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated February 01, 2005 titled 'Ranbaxy receives final approval for Clarithromycin XL 1000 MG Tablet'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has made three fresh filings of its Anti-Retrovirals (ARVs) agents, to the WHO for its approvals. The details of the press release titled 'Ranbaxy HIV update - January 24, 2005' shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd. has informed the Exchange that the company has on January 21,2005 issued a press release titled "Ranbaxy strengthens Top Management team to meet 2007 target of USD 2 Bn". The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on January 18, 2005 issued a press release titled "Ranbaxy 2004 full year sales up 21% at USD 1178 Mn; R&D expenses grow 41%; PAT- marginal growth to USD 164 Mn.". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has on January 10, 2005, announced that the Company has so far made three filings of its Anti-Retrovirals (ARVs), to the USFDA for its approval under the expedited review process of the US Presidents Emergency Plan for AIDS Relief (PEPFAR). The details of the press release titled 'Ranbaxy HIV update - January 2005' shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a Press Release on December 23, 2004 titled "RANBAXY CONFERRED FIVE STAR EXPORT HOUSE STATUS BY DGFT. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 21, 2004 issued a press release titled 'Ranbaxy receives US FDA approval to market Fosinopril Sodium and Hydrochlorothiazide tablets'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 17, 2004 issued a Press release titled 'Ranbaxy receives tentative US FDA approval to market Topiramate tablets'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 16, 2004 issued a press release titled "Ranbaxy Announces the Launch of Quinapril Tablets by Teva, Based on an Agreement between Ranbaxy and Teva." The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 15, 2004 issued a press release titled "RANBAXY GAINS US FDA APPROVAL FOR FLUOXETINE 40MG CAPSULES". The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 13, 2004 issued a press release titled "Ranbaxy receives tentative approval for Gabapentin Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 09, 2004 issued a press release titled "Ranbaxy Fine Chemicals Ltd. awarded ISO 14001:1996 Certification - First Indian laboratory chemical entity to achieve distinction". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on November 29,2004 issued a press release titled "UK Court judgement paves way for launch of Clarithromycin by Ranbaxy.- Abott's patent claims for solvent free drug held invalid.".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on November 22, 2004 issued a press release titled "RANBAXY LAUNCHES FLOTRAL FOR UROLOGICAL DISORDER AMONGST AGEING MALES-SAFE AND CONVENIENT TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA". The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on October 29, 2004 issued a press release titled "Ranbaxy announced filing of ANDA application for Anti-Retroviral Agent." The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on October 25, 2004 issued a press release titled "RANBAXY RECEIVES TENTATIVE APPROVAL FOR CARVEDILOL TABLETS". The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that on October 13, 2004 the company has decided to discontinue all its Rofecoxib formulations with immediate effect from India. Rofecoxib is currently being marketed by Ranbaxy also in Peru, Myanmar and Jordan, where it has a small marketshare. The product is being discontinued in these countries as well. The Company's decision is in conformity with its firm committment to ethical business practices. Merck withdrew Vioxx (Rofecoxib) from the market at the end of Sep 2004. In quick response, Ranbaxy had earlier issued a statement, advisin

Ranbaxy Laboratories Ltd has informed the Exchange that following long term evaluation of Vioxx (Rofecoxib) in the treatment of patients with the risk of developing recurrent polyps, Merck & Co. (Merck) noted "an increased relative risk for cardiovascular events, beginning after 18 months of treatment in the patients taking Rofecoxib compared to those taking Placebo. The results for the first 18 months of this study did not show any increased risk of confirmed cardiovascular events on Rofecoxib." As a result of these findings Merck decided to withdraw Vioxx, on a voluntary basis. Further det

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 30, 2004 announced that they have received approval from the U. S. Food and Drug Administration to manufacture and market Clorazepate Dipotassium Tablets USP, 3.75 mg, 7.5 mg, and 15 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug, Tranxene� Tablets, 3.75 mg, 7.5 mg, and 15 mg, respectively, of Ovation Pharmaceuticals, Inc.. Total market sales for Clorazepat

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 27, 2004 announced that they have received approval from the U. S. Food and Drug Administration to manufacture and market Clarithromycin Tablets USP, 250 mg and 500 mg. The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 23, 2004 announced that Ranbaxy Laboratories Ltd has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended-release Tablets, 10 mg/240 mg (24-Hour Formulation). The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).